ADAP Adaptimmune Therapeutics
- 0.996
- -0.014-1.38%
- 1.000
- +0.004+0.39%
Adaptimmune Therapeutics News
H.C. Wainwright Maintains Adaptimmune Therapeutics(ADAP.US) With Buy Rating, Maintains Target Price $4
Adaptimmune Therapeutics Analyst Ratings
Leerink Partners Maintains Adaptimmune Therapeutics(ADAP.US) With Hold Rating, Maintains Target Price $2
Scotiabank Maintains Adaptimmune Therapeutics(ADAP.US) With Buy Rating, Maintains Target Price $3.15
A Quick Look at Today's Ratings for Adaptimmune Therapeutics(ADAP.US), With a Forecast Between $1 to $4
Scotiabank Sticks to Its Buy Rating for Adaptimmune Therapeutics (ADAP)
Buy Rating Affirmed for Adaptimmune Therapeutics Amidst Promising Product Launch and Strong Pipeline
Adaptimmune Therapeutics: A Cautious Hold Amid Gradual Launch and Long-Term Growth Strategy
Adaptimmune Therapeutics (ADAP) Gets a Sell From Barclays
Mizuho Securities Maintains Adaptimmune Therapeutics(ADAP.US) With Buy Rating
Analysts' Opinions Are Mixed on These Healthcare Stocks: Blueprint Medicines (BPMC), Adaptimmune Therapeutics (ADAP) and Ardelyx (ARDX)
Scotiabank Maintains Adaptimmune Therapeutics(ADAP.US) With Buy Rating, Maintains Target Price $3.15
Scotiabank Remains a Buy on Adaptimmune Therapeutics (ADAP)
Adaptimmune Therapeutics Analyst Ratings
Barclays Maintains Adaptimmune Therapeutics(ADAP.US) With Sell Rating, Maintains Target Price $1
Analysts' Opinions Are Mixed on These Healthcare Stocks: Adaptimmune Therapeutics (ADAP), Lantheus (LNTH) and Vertex Pharmaceuticals (VRTX)
H.C. Wainwright Maintains Adaptimmune Therapeutics(ADAP.US) With Buy Rating, Maintains Target Price $4
JonesTrading Maintains Adaptimmune Therapeutics(ADAP.US) With Buy Rating, Cuts Target Price to $2
Adaptimmune Therapeutics Analyst Ratings
H.C. Wainwright Initiates Adaptimmune Therapeutics(ADAP.US) With Buy Rating, Announces Target Price $4
Analysis
Price Target
No Data
No Data
